You are here:

MS in the Media - 28 September 2018

Published on

21 - 28 September 2018

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Smoking worsens MS

A review of previous research confirms the fact that smoking increases the risk of getting MS in the first place and makes MS progress more quickly.  A survey conducted for the MS Society suggests people with MS are unaware of these risks

Source: iNews
Source: Scotsman

MS Trust link: Smoking

Gilenya for younger people

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that Gilenya (fingolimod) be licensed for treating people with MS aged between 10 and 17. The licence is normally issued about two months after a CHMP recommendation. Gilenya will be the first disease modifying drug licensed for this age group in Europe

Source: News Medical

MS Trust link: Childhood MS

Social networks influence health

The health habits in someone's social group - such as attitudes to exercise, smoking or seeing a doctor - were associated with the level of dysfunction reported by people with MS according to new research

Source: Harvard Gazette

MS Trust link: Wellbeing

Ten years of the Risk-sharing Scheme

The first four disease modifying drugs (Avonex, Betaferon, Copaxone, Rebif) are cost effective treatments according to data from the full ten years of the scheme that made the drugs available in the UK.  The story also looks at the wider benefits of the Scheme in expanding MS services

Source: MS News Today

MS Trust link: Risk-sharing Scheme

Print this page